FDA Alert
Scios Corporation
(
SCIO |
Quote |
Chart |
News |
PowerRating) is
poised to have its new drug to treat congestive heart failure, a disease
affecting over 5 million people in the U.S., confirmed by the FDA on Friday May
25. Today’s medications are not very effective in treating the disease and no
new treatments have been approved for congestive heart failure in the past few
years. Scios’ new drug, Natrecor, is a synthetic version of a hormone produced
in the body that appears to be more effective in improving patients with
congestive heart failure than current therapy. Sales of this drug could top $300
million per year. Look for movement in this company’s stock price on Friday
as the FDA votes on approval.